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The relationship between cancer and 
inflammation is well known since 1863 
when Rudolf Virchow, following the obser-
vation of leukocytes in neoplastic tissues, 
hypothesized that chronic inflamma-
tion could contribute to the tumorigenic 
process. In the following decades, several 
lines of evidence suggested a strong asso-
ciation between chronic inflammation and 
increased susceptibility to neoplastic trans-
formation and cancer development. It was 
estimated that up to 20% of all tumors arise 
from conditions of persistent inflammation 
such as chronic infections or autoimmune 
diseases. Indeed, the associations are well 
known between cervical cancer and papil-
loma virus, gastric cancer and Helicobacter 
pylori induced gastritis, esophageal adeno-
carcinoma and Barrett’s metaplasia, hepa-
tocellular carcinoma, hepatitis B and C viral 
infections, and many others. Some of the 
mechanisms forming the basis of the rela-
tionship between inflammation and tumor 
have been recently elucidated. The inflam-
matory microenvironment of neoplastic 
tissues is characterized by the presence 
of host leukocytes both in the supporting 
stroma and among the tumor cells, with 
macrophages, dendritic cells, mast cells, 
and T cells being differentially distributed 
(Balkwill and Mantovani, 2001). Several 
cytokines (TNF, IL-1, IL-6) and chemokines 
that are produced by the tumor cells and 
by leukocytes and platelets associated with 
the tumor have been found to be able to 
maintain the invasive phenotype (Coussens 
and Werb, 2002). Tumor-associated mac-
rophages (TAMs) are a major component 
of the leukocyte infiltrate, initially recruited 
by inflammatory chemokines (e.g., CCL2) 
and then sustained by cytokines present in 
the tumor microenvironment (e.g., CSFs, 
VEGF-A). In response to cytokines such as 
TGF-β, IL-10, and M-CSF, TAMs promote 
tumor proliferation and progression and 
stroma deposition and, indeed, the density 
of TAMs is increased in advanced thyroid 
cancers (Ryder et al., 2008). As far as pap-
illary thyroid cancer (PTC) is concerned, 
this tumor is frequently associated with 
autoimmune thyroid diseases, Graves’ dis-
ease, and Hashimoto’s thyroiditis. The fre-
quency of association is extremely variable 
in the series from different countries, 0–9% 
for  Graves’ and 9–58% for Hashimoto’s 
(Figure 1). It is still debated whether asso-
ciation with an autoimmune disorder could 
influence the prognosis of PTC. Indeed a 
worse prognosis was reported in few series 
(Ozaki et al., 1990; Pellegriti et al., 1998), 
while the majority of the studies showed 
either a protective effect of thyroid auto-
immunity (Matsubasyashi et al., 1995; Loh 
et al., 1999; Gupta et al., 2001) or a similar 
behavior between cancer with and without 
associated thyroiditis (Yano et al., 2007). 
These discrepancies can be due to either 
the low number of patients examined in 
those studies, the lack of a control group, 
the existence of different genetic and epi-
demiological backgrounds, or the use of 
inappropriate criteria to define remis-
sion or persistence/relapse. We recently 
produced data extending the knowledge 
about the tight relationships among thy-
roiditis and thyroid cancer. In particular, 
the clinical and molecular features, and the 
expression of inflammation-related genes, 
were investigated in a large series of PTCs 
divided in two groups according to the 
association or not of the tumor with thy-
roiditis (Muzza et al., 2010). Interestingly, 
no significant differences between the two 
groups were found, as far as age at diag-
nosis, gender distribution, TNM staging, 
histological variants, and outcome are 
concerned, suggesting that the association 
with an autoimmune thyroid process does 
not modify either the presentation or the 
clinical behavior of PTC. A crucial finding 
of the last few years concerns the genetic 
background of PTCs, since the concept 
has emerged that the inflammatory protu-
mourigenic microenvironment of this can-
cer is elicited by the oncogenes responsible 
for thyroid neoplastic transformation (such 
as RET/PTC, BRAFV600E, and RASG12V; 
Borrello et al., 2005, 2008; Melillo et al., 
2005; Mantovani et al., 2008). In particu-
lar, we recently demonstrated that the RET/
PTC1 oncogene activates a transcriptional 
proinflammatory program in normal 
human primary thyrocytes (Borrello et al., 
2005). Moreover, gene expression studies 
in cellular systems showed that not only 
RET/PTC but also RAS and BRAF proteins, 
all belonging to the RET–PTC/RAS/BRAF/
ERK pathway, are able to induce the up-
regulation of chemokines, which in turn 
could contribute to neoplastic prolifera-
tion, survival, and migration (Melillo et al., 
2005). Consistently, other Authors demon-
strated that RET/PTC3-thyrocytes express 
high levels of proinflammatory cytokines 
(Russel et al., 2003) and proteins involved 
in the immune response (Puxeddu et al., 
2005). These data are well in agreement 
with our recent study which firstly showed 
that PTCs harbor a different genetic back-
ground according to the association or 
not with thyroiditis (Muzza et al., 2010). 
In particular, RET/PTC was more repre-
sented in patients with PTC and autoim-
munity, while BRAF
V600E was significantly 
more frequent in patients with PTC alone. 
Moreover, we showed that the expression of 
genes encoding three inflammation-related 
genes (CCL20, CXCL8, and l-selectin) was 
enhanced either in BRAFV600E or in RET/
PTC tumors, compared with normal sam-
ples. Interestingly, non-neoplastic tissues 
with thyroiditis displayed the same levels of 
expression of CCL20 and CXCL8 compared 
to normal samples, suggesting that these 
inflammatory molecules could be associ-
ated with tumor-related inflammation, and 
not with the autoimmune process.
In conclusion, recent studies opened a 
new and extremely attractive scenario on 
the “connection” between thyroid autoim-
munity, inflammation, and cancer. The 
interest is linked not only to the possibility 
of better understanding the communication 
between abnormally growing cells and their 
microenvironment, but also to the chance to 
pharmacologically interfere with such pro-
tumor interactions.
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